Respiratory Infections News

Outbreaks of coccidioidomycosis, known as valley fever, have reached beyond areas in which it was previously considered endemic, and most stem from the environment, according to researchers.

Amid an historically bad influenza season, researchers said they may have found a safe and effective way to kill airborne pathogens, including influenza viruses.

An experimental vaccine for respiratory syncytial virus, or RSV, boosted pre-existing immune responses in young women and had a safety profile similar to that of the Tdap vaccine, according to the results of a pair of phase 2 trials.

Paratek Pharmaceuticals announced today that it has submitted two new drug applications for once-daily oral and IV formulations of its broad-spectrum antibiotic omadacycline for the treatment of community-acquired bacterial pneumonia, or CABP, and acute bacterial skin and skin structure infections, or ABSSSIs.

There are more signs this week that the United States is experiencing a particularly severe influenza season.

Allergan announced that the FDA approved its supplemental to expand the use of Avycaz to treat hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia, or HABP and VABP.

Influenza vaccination may also protect people against tuberculosis, the world’s No. 1 infectious disease killer, according to results from a large nationwide cohort study in Taiwan.

Like influenza viruses, adenoviruses can cause severe respiratory illness. Unlike influenza, however, not everyone has access to a vaccine.

Patients who were born during the 1957 influenza pandemic appeared to face an increased risk of death in later pandemics, according to researchers in Canada.

Researchers said they developed a urinary antigen test that can detect cases of community-acquired pneumonia that are often missed by traditional tests.